NewLink Genetics Corp (NASDAQ:NLNK) has earned an average rating of “Hold” from the nine analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $4.90.

Several analysts have recently commented on NLNK shares. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Saturday, August 4th. Stifel Nicolaus cut shares of NewLink Genetics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $8.00 to $4.00 in a research note on Wednesday, August 1st. Finally, ValuEngine cut shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 22nd.

Shares of NLNK remained flat at $$2.37 during mid-day trading on Friday. 461,813 shares of the stock traded hands, compared to its average volume of 513,612. NewLink Genetics has a twelve month low of $2.31 and a twelve month high of $12.91. The company has a market capitalization of $88.20 million, a PE ratio of -1.03 and a beta of 1.29.

NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings results on Tuesday, July 31st. The biotechnology company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.12. NewLink Genetics had a negative net margin of 252.18% and a negative return on equity of 53.70%. The business had revenue of $2.25 million for the quarter, compared to analysts’ expectations of $5.85 million. research analysts anticipate that NewLink Genetics will post -1.69 EPS for the current fiscal year.

In other NewLink Genetics news, Director Ernest Talarico III sold 13,806 shares of the firm’s stock in a transaction that occurred on Tuesday, July 10th. The shares were sold at an average price of $4.82, for a total value of $66,544.92. Following the transaction, the director now directly owns 39,365 shares of the company’s stock, valued at $189,739.30. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 12.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its stake in NewLink Genetics by 0.8% in the second quarter. BlackRock Inc. now owns 2,279,452 shares of the biotechnology company’s stock valued at $10,850,000 after acquiring an additional 18,461 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of NewLink Genetics by 20.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 673,885 shares of the biotechnology company’s stock worth $3,208,000 after purchasing an additional 114,650 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of NewLink Genetics by 6,778.1% during the first quarter. JPMorgan Chase & Co. now owns 493,367 shares of the biotechnology company’s stock worth $3,577,000 after purchasing an additional 486,194 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of NewLink Genetics by 10.8% during the first quarter. Wells Fargo & Company MN now owns 413,905 shares of the biotechnology company’s stock worth $3,001,000 after purchasing an additional 40,223 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of NewLink Genetics by 125.8% during the second quarter. Renaissance Technologies LLC now owns 405,100 shares of the biotechnology company’s stock worth $1,928,000 after purchasing an additional 225,668 shares in the last quarter. 42.01% of the stock is currently owned by hedge funds and other institutional investors.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Featured Story: What is a Fiduciary?

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.